CDC20B

Summary

CDC20B (cell division cycle 20B, HGNC:24222) is a protein-coding gene on chromosome 5q11.2, encoding Cell division cycle protein 20 homolog B (Q86Y33). Protein regulator of centriole-deuterosome disengagement and subsequently participates in the ciliogenesis in multiciliated cells (MCCs).

Predicted to enable anaphase-promoting complex binding activity and ubiquitin ligase activator activity. Involved in de novo centriole assembly. Located in deuterosome.

Source: NCBI Gene 166979 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 109 total
• MANE Select transcript: NM_001170402

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:24222
Approved symbol	CDC20B
Name	cell division cycle 20B
Location	5q11.2
Locus type	gene with protein product
Status	Approved
Aliases	FLJ37927
Ensembl gene	ENSG00000164287
Ensembl biotype	protein_coding
OMIM	620335
Entrez	166979

Gene structure

Transcript identifiers

Ensembl transcripts: 5 — 3 protein_coding, 2 nonsense_mediated_decay

ENST00000296733, ENST00000322374, ENST00000381375, ENST00000507931, ENST00000513180

RefSeq mRNA: 3 — MANE Select: NM_001170402 NM_001145734, NM_001170402, NM_152623

CCDS: CCDS3966, CCDS47207, CCDS54852

Canonical transcript exons

ENST00000381375 — 12 exons

Exon	Start	End
ENSE00001083099	55133412	55133528
ENSE00001083106	55128421	55128617
ENSE00001083133	55127257	55127351
ENSE00001083150	55140314	55140407
ENSE00001263609	55143513	55143643
ENSE00001263615	55146628	55146856
ENSE00001263621	55172588	55172650
ENSE00002042568	55112971	55114318
ENSE00002050096	55172938	55173177
ENSE00003469235	55120425	55120550
ENSE00003553164	55119801	55119918
ENSE00003624223	55124803	55125028

Expression profiles

Bgee: expression breadth broad, 50 present calls, max score 80.68.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.1332 / max 23.0403, expressed in 43 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
61685	0.0714	29
61684	0.0618	19

Top tissues by expression

226 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
secondary oocyte	CL:0000655	80.68	gold quality
buccal mucosa cell	CL:0002336	80.27	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	77.67	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	77.14	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	73.29	gold quality
bronchial epithelial cell	CL:0002328	67.90	gold quality
oviduct epithelium	UBERON:0004804	66.96	gold quality
bronchus	UBERON:0002185	66.66	gold quality
left testis	UBERON:0004533	62.96	gold quality
testis	UBERON:0000473	62.33	gold quality
right testis	UBERON:0004534	62.16	gold quality
epithelium of nasopharynx	UBERON:0001951	61.13	silver quality
nasal cavity mucosa	UBERON:0001826	58.23	gold quality
oocyte	CL:0000023	54.90	gold quality
nasal cavity epithelium	UBERON:0005384	53.60	gold quality
endometrium	UBERON:0001295	51.27	gold quality
skin of hip	UBERON:0001554	51.05	gold quality
tendon of biceps brachii	UBERON:0008188	51.04	gold quality
lower lobe of lung	UBERON:0008949	50.77	silver quality
biceps brachii	UBERON:0001507	49.27	gold quality
fallopian tube	UBERON:0003889	48.02	gold quality
hindlimb stylopod muscle	UBERON:0004252	46.00	gold quality
adult mammalian kidney	UBERON:0000082	45.94	gold quality
mucosa of paranasal sinus	UBERON:0005030	45.78	silver quality
upper leg skin	UBERON:0004262	45.15	silver quality
middle temporal gyrus	UBERON:0002771	44.81	gold quality
ventricular zone	UBERON:0003053	44.62	gold quality
sural nerve	UBERON:0015488	44.28	gold quality
kidney	UBERON:0002113	44.20	gold quality
deltoid	UBERON:0001476	44.07	gold quality

Single-cell (SCXA)

Detected in 4 experiment(s), a significant marker in 3.

Experiment	Marker?	Max mean expression
E-MTAB-10283	yes	1153.01
E-CURD-114	yes	652.81
E-ANND-3	yes	4.99
E-ENAD-27	no	3.75

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

92 targeting CDC20B, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4455	100.00	65.48	1587
HSA-MIR-4262	100.00	73.26	3931
HSA-MIR-4481	100.00	66.42	1669
HSA-MIR-6748-5P	100.00	65.81	1057
HSA-MIR-10401-5P	99.99	65.79	948
HSA-MIR-181A-5P	99.99	72.96	2995
HSA-MIR-181B-5P	99.99	72.97	2996
HSA-MIR-181C-5P	99.99	72.95	2996
HSA-MIR-181D-5P	99.99	73.04	2997
HSA-MIR-302C-5P	99.97	72.56	3642
HSA-MIR-6825-5P	99.96	69.81	3431
HSA-MIR-651-3P	99.94	73.48	5177
HSA-MIR-3143	99.93	71.96	3104
HSA-MIR-1305	99.91	71.43	3443
HSA-MIR-1297	99.91	73.41	3162
HSA-MIR-6780A-5P	99.88	66.69	2776
HSA-MIR-548D-3P	99.87	70.67	4362
HSA-MIR-548BB-3P	99.86	70.58	4354
HSA-MIR-369-3P	99.85	70.52	2264
HSA-MIR-4728-5P	99.85	69.39	4718
HSA-MIR-548AC	99.84	70.77	4351
HSA-MIR-548H-3P	99.84	70.80	4349
HSA-MIR-548Z	99.84	70.80	4349
HSA-MIR-548AJ-5P	99.78	71.12	3085
HSA-MIR-548F-5P	99.78	71.02	3093
HSA-MIR-548G-5P	99.78	71.12	3085
HSA-MIR-548X-5P	99.78	71.12	3085
HSA-MIR-1273H-5P	99.77	66.32	2471
HSA-MIR-4306	99.72	70.50	3630
HSA-MIR-30B-3P	99.70	65.76	2325

Literature-anchored findings (GeneRIF, showing 2)

• CDC20B protein associates to deuterosomes and is required for centriole release and subsequent cilia production. (PMID:30405130)
• Circular RNA hsa_circ_0008896 accelerates atherosclerosis by promoting the proliferation, migration and invasion of vascular smooth muscle cells via hsa-miR-633/CDC20B (cell division cycle 20B) axis. (PMID:35212610)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Cdc20b	ENSMUSG00000078926
drosophila_melanogaster	fzy	FBGN0001086

Paralogs (2): FZR1 (ENSG00000105325), CDC20 (ENSG00000117399)

Protein

Protein identifiers

Cell division cycle protein 20 homolog B — Q86Y33 (reviewed: Q86Y33)

All UniProt accessions (1): Q86Y33

UniProt curated annotations — full annotation on UniProt →

Function. Protein regulator of centriole-deuterosome disengagement and subsequently participates in the ciliogenesis in multiciliated cells (MCCs).

Subcellular location. Cytoplasm.

Tissue specificity. Expressed in multiciliated cells (MCCs).

Similarity. Belongs to the WD repeat CDC20/Fizzy family.

Isoforms (5)

UniProt ID	Names	Canonical?
Q86Y33-1	1	yes
Q86Y33-2	2
Q86Y33-3	3
Q86Y33-4	4
Q86Y33-5	5

RefSeq proteins (3): NP_001139206, NP_001163873, NP_689836 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001680	WD40_rpt	Repeat
IPR015943	WD40/YVTN_repeat-like_dom_sf	Homologous_superfamily
IPR019775	WD40_repeat_CS	Conserved_site
IPR033010	Cdc20/Fizzy	Family
IPR036322	WD40_repeat_dom_sf	Homologous_superfamily
IPR056150	WD40_CDC20-Fz	Domain

Pfam: PF24807

UniProt features (24 total): repeat 7, splice variant 7, sequence variant 6, compositionally biased region 2, chain 1, region of interest 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q86Y33-F1	69.60	0.50

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 120 (showing top): E2F_Q4_01, GOBP_REGULATION_OF_PROTEASOMAL_UBIQUITIN_DEPENDENT_PROTEIN_CATABOLIC_PROCESS, BENPORATH_ES_WITH_H3K27ME3, GOBP_ANAPHASE_PROMOTING_COMPLEX_DEPENDENT_CATABOLIC_PROCESS, GOBP_POSITIVE_REGULATION_OF_PROTEIN_CATABOLIC_PROCESS, GOBP_MACROMOLECULE_CATABOLIC_PROCESS, CCANNAGRKGGC_UNKNOWN, GOBP_CENTRIOLE_ASSEMBLY, E2F1DP1_01, E2F_Q3, E2F1DP2_01, GOBP_REGULATION_OF_CATABOLIC_PROCESS, GOBP_POSITIVE_REGULATION_OF_CATABOLIC_PROCESS, GOBP_ORGANELLE_ASSEMBLY, GOBP_REGULATION_OF_PROTEIN_CATABOLIC_PROCESS

GO Biological Process (4): anaphase-promoting complex-dependent catabolic process (GO:0031145), de novo centriole assembly (GO:0097742), positive regulation of anaphase-promoting complex-dependent catabolic process (GO:1905786), positive regulation of ubiquitin protein ligase activity (GO:1904668)

GO Molecular Function (4): anaphase-promoting complex binding (GO:0010997), ubiquitin ligase activator activity (GO:1990757), protein binding (GO:0005515), ubiquitin-protein transferase activator activity (GO:0097027)

GO Cellular Component (3): anaphase-promoting complex (GO:0005680), cytoplasm (GO:0005737), deuterosome (GO:0098536)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
proteasome-mediated ubiquitin-dependent protein catabolic process	1
centriole assembly	1
anaphase-promoting complex-dependent catabolic process	1
positive regulation of proteasomal ubiquitin-dependent protein catabolic process	1
regulation of anaphase-promoting complex-dependent catabolic process	1
positive regulation of ubiquitin-protein transferase activity	1
ubiquitin protein ligase activity	1
regulation of ubiquitin protein ligase activity	1
protein-containing complex binding	1
ubiquitin-protein transferase activator activity	1
positive regulation of ubiquitin protein ligase activity	1
binding	1
ubiquitin-protein transferase activity	1
enzyme activator activity	1
ubiquitin-protein transferase regulator activity	1
nuclear ubiquitin ligase complex	1
cullin-RING ubiquitin ligase complex	1
intracellular anatomical structure	1
cellular anatomical structure	1
intracellular membraneless organelle	1

Protein interactions and networks

STRING

2867 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CDC20B	CDK6	Q00534	745
CDC20B	CDC25A	P30304	742
CDC20B	CCNO	P22674	681
CDC20B	E2F1	Q01094	652
CDC20B	DEUP1	Q05D60	628
CDC20B	MCIDAS	D6RGH6	591
CDC20B	FOXJ1	Q92949	485
CDC20B	GMNC	A6NCL1	456
CDC20B	LINC03043	A4D0Y5	430
CDC20B	FOXN4	Q96NZ1	427
CDC20B	OR5I1	Q13606	420
CDC20B	CCP110	O43303	412
CDC20B	HDAC1	Q13547	393
CDC20B	PTTG2	Q9NZH5	387
CDC20B	ESPL1	Q14674	378

IntAct

42 interactions, top by confidence:

A	B	Type	Score
CDC20B	TRIM37	psi-mi:“MI:0915”(physical association)	0.560
TRIM27	CDC20B	psi-mi:“MI:0915”(physical association)	0.560
CDC20B	TRIM23	psi-mi:“MI:0915”(physical association)	0.560
MAGEA11	CDC20B	psi-mi:“MI:0915”(physical association)	0.560
GOLGA2	CDC20B	psi-mi:“MI:0915”(physical association)	0.560
TRAF2	CDC20B	psi-mi:“MI:0915”(physical association)	0.560
CDC20B	KRT31	psi-mi:“MI:0915”(physical association)	0.560
CDC20B	CCDC57	psi-mi:“MI:0915”(physical association)	0.560
CDC20B	MTUS2	psi-mi:“MI:0915”(physical association)	0.560
KRT40	CDC20B	psi-mi:“MI:0915”(physical association)	0.560
SPAG5	CDC20B	psi-mi:“MI:0915”(physical association)	0.560
CDC20B	PLK2	psi-mi:“MI:0915”(physical association)	0.560
CDC20B	TRIM27	psi-mi:“MI:0915”(physical association)	0.560
CDC20B	MAGEA11	psi-mi:“MI:0915”(physical association)	0.560
CDC20B	GOLGA2	psi-mi:“MI:0915”(physical association)	0.560
CDC20B	TRAF2	psi-mi:“MI:0915”(physical association)	0.560
MTUS2	CDC20B	psi-mi:“MI:0915”(physical association)	0.560
CDC20B	KRT40	psi-mi:“MI:0915”(physical association)	0.560
TRIM37	CDC20B	psi-mi:“MI:0915”(physical association)	0.560
TRIM23	CDC20B	psi-mi:“MI:0915”(physical association)	0.560

BioGRID (47): CDC20B (Two-hybrid), CDC20B (Two-hybrid), CDC20B (Two-hybrid), CDC20B (Two-hybrid), CDC20B (Two-hybrid), CDC20B (Two-hybrid), CDC20B (Two-hybrid), CDC20B (Two-hybrid), CDC20B (Two-hybrid), CDC20B (Two-hybrid), CDC20B (Two-hybrid), CCDC57 (Two-hybrid), CDC20B (Affinity Capture-MS), UBA5 (Affinity Capture-MS), MAN2C1 (Affinity Capture-MS)

ESM2 similar proteins: A0A1L8GXY4, A0A1L8I2C5, A1A5R7, A6PWY4, A9X1C6, B1ANS9, B2KIQ4, D3Z3I0, E9Q7R9, F1QHZ6, O13286, O74845, O94411, P26309, P43254, P51956, P93471, Q09786, Q4V837, Q5R6T6, Q5TKR9, Q5XHI9, Q5ZKI7, Q6DTM3, Q6GM71, Q6GPU3, Q6VZ17, Q7Z2W4, Q80Z32, Q86VD1, Q86Y33, Q8BZ21, Q8CDP0, Q8K3E5, Q8L4H0, Q8N157, Q8N4N8, Q8NA75, Q8NDM7, Q8NEM8

Diamond homologs: A0A1L8I2C5, A0A396ISC0, D3Z3I0, F4K5R6, O13286, O65418, O94423, P26309, P53197, P78972, Q12834, Q1HPW4, Q3E906, Q4PSE4, Q54KM3, Q54MZ3, Q5H7C0, Q62623, Q86Y33, Q8L3Z8, Q8LPL5, Q8VZS9, Q9FN19, Q9JJ66, Q9M7I2, Q9R1K5, Q9S7H3, Q9S7I8, Q9SZA4, Q9UM11, A3LQ86, O94411, O94620, P25387, Q09786, Q15269, Q5RFQ3, Q8NEZ3, Q93134, Q9P783

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

109 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	90
Likely benign	8
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

2236 predictions. Top by Δscore:

Variant	Effect	Δscore
5:55125025:CCCA:C	acceptor_gain	1.0000
5:55125026:CCA:C	acceptor_gain	1.0000
5:55125026:CCAC:C	acceptor_gain	1.0000
5:55125027:CA:C	acceptor_gain	1.0000
5:55125027:CAC:C	acceptor_gain	1.0000
5:55125029:C:CC	acceptor_gain	1.0000
5:55128509:A:AC	donor_gain	1.0000
5:55128509:AAGT:A	donor_gain	1.0000
5:55128510:A:C	donor_gain	1.0000
5:55133410:A:AC	donor_gain	1.0000
5:55133411:C:CC	donor_gain	1.0000
5:55160397:G:GG	donor_gain	1.0000
5:55172586:A:AC	donor_gain	1.0000
5:55172587:C:CC	donor_gain	1.0000
5:55172646:CTTTC:C	acceptor_gain	1.0000
5:55172934:TCAC:T	donor_loss	1.0000
5:55172935:CA:C	donor_loss	1.0000
5:55172936:A:AC	donor_gain	1.0000
5:55172936:AC:A	donor_gain	1.0000
5:55172936:ACC:A	donor_gain	1.0000
5:55172937:C:CT	donor_gain	1.0000
5:55172937:CC:C	donor_gain	1.0000
5:55172937:CCC:C	donor_gain	1.0000
5:55172937:CCCA:C	donor_gain	1.0000
5:55125037:T:C	acceptor_gain	0.9900
5:55125037:T:TC	acceptor_gain	0.9900
5:55125040:C:CT	acceptor_gain	0.9900
5:55127352:C:CC	acceptor_gain	0.9900
5:55128419:A:AC	donor_gain	0.9900
5:55128420:C:CC	donor_gain	0.9900

AlphaMissense

3401 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
5:55127259:G:C	S329R	0.996
5:55127259:G:T	S329R	0.996
5:55127261:T:G	S329R	0.996
5:55125028:A:C	S330R	0.994
5:55125028:A:T	S330R	0.994
5:55127258:T:G	S330R	0.994
5:55125026:C:T	G331E	0.991
5:55125027:C:A	G331W	0.990
5:55124902:G:C	S372R	0.988
5:55124902:G:T	S372R	0.988
5:55124904:T:G	S372R	0.988
5:55124931:A:G	W363R	0.988
5:55124931:A:T	W363R	0.988
5:55128443:C:T	G291D	0.987
5:55128449:G:T	A289E	0.986
5:55127279:A:G	W323R	0.985
5:55127279:A:T	W323R	0.985
5:55127348:A:G	W300R	0.983
5:55127348:A:T	W300R	0.983
5:55124803:C:A	K405N	0.982
5:55124803:C:G	K405N	0.982
5:55125024:A:G	S332P	0.981
5:55128444:C:G	G291R	0.980
5:55127263:A:G	L328P	0.979
5:55128578:G:T	A246D	0.979
5:55119872:C:T	G463D	0.978
5:55128474:A:G	W281R	0.977
5:55128474:A:T	W281R	0.977
5:55127293:A:T	V318D	0.976
5:55128450:C:G	A289P	0.975

dbSNP variants (sampled 300 via entrez): RS1000008120 (5:55169268 A>T), RS1000013840 (5:55124488 T>G), RS1000032277 (5:55154524 A>G), RS1000064221 (5:55161974 G>A,T), RS1000079331 (5:55117900 A>C), RS1000204806 (5:55163201 T>C), RS1000259581 (5:55143723 T>C), RS1000294198 (5:55130790 G>A,C), RS1000317488 (5:55136908 C>A), RS1000321443 (5:55117099 T>A,G), RS1000327497 (5:55136592 A>G), RS1000336973 (5:55124751 A>G), RS1000390144 (5:55170864 A>G,T), RS1000459556 (5:55163629 C>T), RS1000543736 (5:55161750 A>G)

Disease associations

OMIM: gene MIM:620335 | disease phenotypes: MIM:613659

GenCC curated gene-disease

Mondo (1): gastric cancer (MONDO:0001056)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST008399_7	Cocaine dependence	8.000000e-06

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB variants

1 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs10061133	CDC20B, MIR449A, MIR449B		0.00	0

CTD chemical–gene interactions

36 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol A	increases expression, increases methylation	2
Benzo(a)pyrene	decreases expression, increases methylation	2
tetrabromobisphenol S	increases expression	1
methylmercuric chloride	increases expression	1
methyleugenol	decreases expression	1
2,3-pentanedione	decreases expression	1
sodium arsenite	decreases expression	1
tetrabromobisphenol A	increases expression	1
S-(1,2-dichlorovinyl)cysteine	affects response to substance, increases expression, affects cotreatment	1
perfluorooctane sulfonic acid	decreases expression	1
perfluoro-n-nonanoic acid	decreases expression	1
abrine	increases expression	1
Grape Seed Proanthocyanidins	decreases expression, affects cotreatment	1
2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine	increases expression, increases response to substance	1
Rosiglitazone	decreases expression	1
Troglitazone	decreases expression	1
Vorinostat	decreases expression	1
Acetaminophen	decreases expression	1
Air Pollutants	increases abundance, increases expression	1
Cadmium	decreases expression, increases abundance	1
Catechin	affects cotreatment, decreases expression	1
Diacetyl	decreases expression	1
Diethylhexyl Phthalate	decreases expression	1
Endosulfan	affects cotreatment, decreases expression	1
Estradiol	decreases expression	1
Lead	decreases expression	1
Lipopolysaccharides	increases expression, affects response to substance, affects cotreatment	1
Smoke	increases abundance, increases expression	1
Tetrachlorodibenzodioxin	affects cotreatment, decreases expression	1
Thimerosal	increases expression	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00365508	PHASE4	COMPLETED	Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking
NCT00558155	PHASE4	COMPLETED	The Impact of Immunostimulating Nutrition on the Outcome of Surgery
NCT00576940	PHASE4	COMPLETED	Standard and Immunostimulating Enteral Nutrition in Surgical Patients
NCT00666978	PHASE4	COMPLETED	Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking
NCT01038154	PHASE4	UNKNOWN	Study to Evaluate the Efficacy of Pravastatin on Survival and Recurrence of Advanced Gastroesophageal Cancer
NCT01234272	PHASE4	COMPLETED	Comparison of the Analgesic Effect Between Intrathecal Morphine and IV-fentanyl Patient Controlled Analgesia (ITM-IVPCA) and Epidural PCA (PCEA) in Patients Undergoing Gastrectomy -Randomized Allocation Study-
NCT01260194	PHASE4	TERMINATED	A Study of Herceptin (Trastuzumab) in Combination With Standard Chemotherapy in Patients With HER Positive Metastatic Gastric Cancer
NCT01271582	PHASE4	UNKNOWN	Investigation of Association Between UGT1A1 Polymorphisms and Irinotecan Toxicity in Korean Patients
NCT01401075	PHASE4	COMPLETED	RCT With Adjuvant Mistletoe Treatment in Gastric Cancer Patients
NCT01471756	PHASE4	COMPLETED	Improving Complete Endoscopic Mucosal Resection (EMR) of Colorectal Neoplasia
NCT01766765	PHASE4	UNKNOWN	Early Jejunostomy Nutrition Minimizes Time to Chemotherapy
NCT01910948	PHASE4	UNKNOWN	Perioperative Application of Omega-3 Polyunsaturated Fatty Acids in Gastric Cancer Patients
NCT01927328	PHASE4	UNKNOWN	Iron Replacement in Oesophagogastric Neoplasia
NCT01962272	PHASE4	COMPLETED	The Effect of Nutritional Counseling for Cancer Patients
NCT01962376	PHASE4	UNKNOWN	Preoperative Chemotherapy With Bevacizumab For Potentially Resectable Gastric Cancer With Liver Metastasis
NCT02047994	PHASE4	RECRUITING	Multicentric Randomized Study of H. Pylori Eradication and Pepsinogen Testing for Prevention of Gastric Cancer Mortality
NCT02235246	PHASE4	COMPLETED	The Effect of Perioperative Intravenous Magnesium on Pain After Endoscopic Submucosal Dissection for Gastric Neoplasm: Prospective Randomized Double-blind Placebo Controlled Study
NCT02366819	PHASE4	SUSPENDED	Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
NCT02401971	PHASE4	UNKNOWN	Irinotecan Plus Thalidomide in Second Line Advanced Gastric Cancer
NCT02458573	PHASE4	COMPLETED	Comparison of the Effects of Continuous Epidural Analgesia and Continuous Intravenous Analgesia on Postoperative Bowel Movement in Patients Undergoing Laparoscopic Gastrectomy
NCT02638584	PHASE4	COMPLETED	Effects of Ilaprazole on Ulcer Healing Rate and Prevention of Gastrointestinal Bleeding in the Patients Undergone ESD.
NCT02776527	PHASE4	UNKNOWN	A Clinical Trial of Maintenance Treatment of Apatinib in Advanced Gastric Cancer Patients Have Completed Postoprative Adjuvant Chemotherapy
NCT03384511	PHASE4	COMPLETED	The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.
NCT03550482	PHASE4	COMPLETED	Oncoxin® and Quality of Life in Cancer Patients
NCT03609892	PHASE4	COMPLETED	Helicobacter Rescue Therapy With Berberine Plus Amoxicillin Quadruple Therapy Versus Tetracycline Plus Furazolidone Quadruple Therapy
NCT03642093	PHASE4	UNKNOWN	HOPE - A Study to Evaluate the Effect of a Prehabilitation Program on GI Cancer Patients Planning to Undergo Surgery
NCT03733639	PHASE4	UNKNOWN	Tisseel® as a Reinforcement of Esophagojejunal Anastomoses
NCT04168346	PHASE4	NOT_YET_RECRUITING	Preoperative Intravenous Iron Therapy in Patients With Gastric Cancer
NCT04209933	PHASE4	COMPLETED	Helicobacter Pylori Eradication With Different Bismuth Quadruple Therapies
NCT04591028	PHASE4	WITHDRAWN	A Study to Evaluate Indocyanine Green Lymphangiography to Improve Lymphadenectomy in Gastric Cancer Patients
NCT04607057	PHASE4	UNKNOWN	Supplemental Parenteral Nutrition During Postgastrectomy in Nutritionally at Risk Patient
NCT04660123	PHASE4	COMPLETED	A Real World Study of Bismuth Colloidal Pectin Granules Quadruple Therapy for H. Pylori Eradication
NCT04678492	PHASE4	COMPLETED	Helicobacter Rescue Therapy With High-dose Esomeprazole and Amoxicillin Dual Therapy Versus Bismuth-containing Quadruple Therapy
NCT04697186	PHASE4	COMPLETED	Helicobacter Pylori Eradication With Berberine Plus Amoxicillin Triple Therapy Versus Bismuth-containing Quadruple Therapy
NCT05029453	PHASE4	UNKNOWN	Apatinib Combined With Chemotherapy Versus Chemotherapy in Second-line Gastric Cancer Receiving Prior Anti-PD-1 Therapy
NCT05183126	PHASE4	RECRUITING	Pharmacokinetic Study of Skeletal Muscle Area-based Paclitaxel Infusion in Patients With Cancer
NCT05354856	PHASE4	TERMINATED	The Effect of Chemoradiotherapy on Gastric Perfusion in Patients With Gastric Cancer.
NCT05410535	PHASE4	COMPLETED	To Evaluate Efficacy of Ursodeoxycholic Acid (UDCA) for the Prevention of Gallstone Formation After Gasterectomy
NCT05498766	PHASE4	NOT_YET_RECRUITING	Effect and Safety of Huaier Granule Versus SOX Regimen in Gastric Cancer Patients
NCT05518929	PHASE4	COMPLETED	Hypoxia During Gastroenterological Endoscope Procedures Sedated With Ciprofol In Overweight Or Obesity Patients